Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) was the target of a significant decline in short interest during the month of September. As of September 15th, there was short interest totaling 351,459 shares, a decline of 43.4% from the August 31st total of 620,909 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 36 shares, the short-interest ratio is presently 9,762.8 days.

Analyst Upgrades and Downgrades

BIOVF has been the topic of a number of recent research reports. Pareto Securities cut shares of Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research report on Friday, July 3rd. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, July 21st. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Swedish Orphan Biovitrum presently has an average rating of “Moderate Buy”.

Swedish Orphan Biovitrum Price Performance

Swedish Orphan Biovitrum stock opened at $42.90 on Friday. The company’s 50 day simple moving average is $47.88 and its 200 day simple moving average is $46.21. Swedish Orphan Biovitrum has a fifty-two week low of $33.30 and a fifty-two week high of $49.03. The firm has a market capitalization of $15.27 billion, a price-to-earnings ratio of 95.34 and a beta of 0.47. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB, commonly known as Sobi, is a Sweden-based biopharmaceutical company focused on developing, manufacturing and commercializing treatments for rare diseases. Its activities center on conditions in hematology, immunology and specialty care, where patients often have limited treatment options.

Sobi’s portfolio includes therapies for hemophilia and other bleeding disorders, immune-mediated diseases, and rare inflammatory or hematologic conditions. Its products include Elocta and Alprolix for hemophilia, Doptelet for certain platelet disorders, Gamifant for primary hemophagocytic lymphohistiocytosis, and Aspaveli for paroxysmal nocturnal hemoglobinuria.